Developer docs
API playgroundTry for free, no card

Search company profiles

Axio BioPharma

Full company profile

uuid0000lwu

Namestring
Axio BioPharma
Legal namestring
Axio BioPharma Inc.
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Axio BioPharma is a Seed-stage biotechnology company founded in 2024 in Madison, Wisconsin, building a vendor-neutral data network for biopharma. The company operates a platform-plus-modules architecture: Axio Forge is a US-based high-throughput biologics laboratory producing approximately 100 monoclonal antibodies per week with 3-5 week turnaround using CHO and HEK293 expression systems, running on a fee-for-service revenue model. Axio Lattice is a federated intelligence platform in development, comprising four components — Node (local system connections), Rosetta (standardization layer), Blueprints (pre-built workflows), and Signal (pattern surfacing) — designed to connect manufacturing process data across sponsor and CDMO sites without centralizing it, enabling cross-site tech transfer, batch decisions, and investigations via a planned recurring subscription model. The company's BAMI (Biomanufacturing AI Maturity Index) is a six-level assessment framework across five dimensions that functions as thought-leadership content marketing and a top-of-funnel for Lattice adoption.

The company's go-to-market is enterprise field sales targeting two primary customer segments: biotech companies developing biologic therapeutics (seeking faster process understanding and tech transfer) and contract development and manufacturing organizations (seeking to standardize knowledge and scale intelligence across sites). Distribution is single-country/domestic through direct engagement led by Chief Commercial Officer Dave Watrous. The company was founded by Justin Byers (CEO) and Brian Staats (CTO, 20+ years bioinformatics) and has assembled an advisory board including former Catalent VP R&D Greg Bleck, biologics veteran Graham Brearley, Samsung Biologics/Jubilant alumnus Patrick Haffey, and Jim Wilson (ZEA Biosciences CEO, Shepherd Ventures III). Axio was named a Round 1 awardee of the Innovation to Commercialization Pipeline program led by Forward BIOLABS and BioForward Wisconsin in February 2026.

Axio's core competitive thesis is structural neutrality — large CDMOs cannot credibly host a cross-sponsor data network and sponsors will not place proprietary process data on a competitor's platform, so an independent vendor is positioned as the only viable coordinator. The wet-lab Forge engine generates real manufacturing data that seeds the Lattice network, and each deployment compounds reusable schemas and connectors. The company is privately held at Seed stage with approximately $1.4M in disclosed funding; no revenue figures or named customer logos have been disclosed.

Short descriptiontext

Axio BioPharma builds a vendor-neutral data network for biopharma, combining a high-throughput monoclonal antibody lab (Forge) in Madison, WI with an in-development federated intelligence platform (Lattice), serving biotech sponsors and CDMOs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics manufacturing software, monoclonal antibody production, federated data platform, biopharma AI readiness, process development lab
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAI
AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Manufacturing Software & Data Infrastructure
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Axio Forge - Fee-for-Service Lab
TypeProfessional Services
Description

Non-GMP antibody lab providing fee-for-service revenue. High-throughput antibody lab generating fee-for-service revenue. Zero incremental capex for current growth. Generates real manufacturing data that seeds the Lattice network.

axiobiopharma.com
2Axio Lattice - Subscription Platform
TypeSubscription Recurring
Description

Federated data platform with recurring subscription revenue. Vendor-neutral infrastructure connecting manufacturing data across sponsors and CDMOs. Data stays local; meaning is standardized. High-margin recurring revenue model.

axiobiopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Fee-for-service laboratory execution
ModelOtherBilling cadencePay-as-you-go
Notes

Non-GMP antibody lab operating on fee-for-service basis - specific pricing not publicly disclosed

axiobiopharma.com
2Federated data platform subscription
ModelSubscriptionBilling cadenceMonthly
Notes

Recurring subscription for Lattice platform access - specific pricing tiers not publicly disclosed

axiobiopharma.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Forge
Description

High-throughput monoclonal antibody (mAb) production lab in Madison, WI offering ~100 antibodies/week with 3-5 week turnaround using CHO and HEK293 expression systems.

axiobiopharma.com
+2 more records
Core offering1 text field

Axio BioPharma provides AI-ready biologics manufacturing through two integrated offerings: Axio Forge, a US-based high-throughput laboratory producing approximately 100 monoclonal antibodies per week with 3–5 week turnaround using CHO and HEK293 expression systems on a fee-for-service basis; and Axio Lattice, a federated intelligence data platform (in development) that connects and standardizes manufacturing process data across sponsor and CDMO sites without replacing existing systems or centralizing raw data. The offerings are supported by the BAMI (Biomanufacturing AI Maturity Index), a six-level framework and self-assessment tool that evaluates AI readiness across five dimensions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Axio BioPharma offers a platform-plus-modules architecture centered on AI-ready biologics manufacturing. The core offerings are Axio Forge (a US-based high-throughput antibody lab providing fee-for-service mAb production) and Axio Lattice (a federated data intelligence platform under development that connects manufacturing data across sponsors and CDMOs without centralizing it). The BAMI (Biomanufacturing AI Maturity Index) assessment framework complements the platform by helping organizations evaluate their AI readiness across five dimensions. Forge generates real execution data that informs Lattice development, while Lattice is designed to enable cross-site process intelligence, investigations, and decision-making.

Product and service2 records
1Axio Forge
CategoryContract research / laboratory services
Description

US-based high-throughput biologics laboratory in Madison, Wisconsin providing fee-for-service monoclonal antibody production. Produces approximately 100 antibodies per week with a 3–5 week turnaround, supporting CHO and HEK293 transient expression systems, Protein A purification, and standard analytics (purity, aggregation, yield). End-to-end workflow from sequence or plasmid to purified antibody with direct bench-scale scientist access and automated DOE.

2Axio Lattice
CategoryBiopharma data platform / federated intelligence software
Description

Federated intelligence data platform (in development) connecting process data across sites, systems, and partners without replacing existing technology stacks or centralizing raw data. Comprises Node (connects to local systems), Rosetta (standardizes structure and terminology), Blueprints (pre-built workflows), and Signal (surfaces patterns and decision support). Supports tech transfer, batch decisions, cross-site comparability, and investigations across sponsors and CDMOs on a recurring subscription model.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Forward BIOLABS leads the Innovation to Commercialization Pipeline (ICP) program in partnership with BioForward Wisconsin. Axio BioPharma was selected as a Round 1 awardee of the ICP program, which supports early-stage biohealth companies across Wisconsin with targeted resources to reduce commercialization risk, accelerate growth, and strengthen investment readiness.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

BioForward Wisconsin is the unified voice of Wisconsin's biohealth industry and lead organization for the Wisconsin Biohealth Tech Hub. Partners with Forward BIOLABS on the ICP program to support early-stage biohealth companies including Axio BioPharma.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides a federated, vendor-neutral scientific data cloud for life sciences R&D and manufacturing, with AI-ready data lake architecture. Highly comparable to Axio Lattice in approach (data stays local, meaning is standardized) and target customers (biopharma sponsors and CDMOs).

TypeDirect peer
Description

Cloud-based informatics platform for biotech R&D, including biologics development. Comparable in serving modern, AI-forward biologics teams with structured data capture, though focused upstream of manufacturing where Axio Lattice targets cross-site process intelligence.

3Sapio Sciences
TypeDirect peer
Description

LIMS/ELN platform with growing AI and lab automation capabilities, serving biopharma and CDMOs. Comparable as an informatics vendor modernizing lab and process data capture for biologics workflows.

TypeDirect peer
Description

Enterprise biopharma R&D and bioprocess informatics platform used across large biologics sponsors. Comparable as a deep bioprocess data platform targeting similar sponsor customers with structured process data.

TypeDirect peer
Description

Scientific R&D informatics platform (LIMS, ELN, data management) used across biopharma. Comparable as a vendor offering structured data infrastructure that biopharma teams can extend into manufacturing workflows.

TypeDirect peer
Description

Biopharma data management and process informatics platform with strong bioprocess heritage. Comparable as an established informatics vendor serving biopharma R&D and manufacturing data needs.

TypeEmerging player
Description

AI platform purpose-built for biopharma manufacturing with GMP data cloud and analytics. Comparable as a focused biomanufacturing AI vendor but more narrowly applied to batch analytics rather than cross-site federated coordination.

TypeBroad incumbent
Description

Dominant life sciences cloud platform with Vault-based manufacturing, quality, and clinical solutions deeply embedded in pharma sponsors and CDMOs. Comparable as an incumbent data platform, though not vendor-neutral across sponsor/CDMO boundaries — exactly the gap Axio targets.

TypeBroad incumbent
Description

Scientific informatics suite covering lab, formulation, and bioprocess workflows for large biopharma. Comparable as an incumbent serving biomanufacturing data needs with deep installed base, though typically deployed within single organizations rather than across sponsor/CDMO networks.

TypeEmerging player
Description

Manufacturing intelligence and execution platform for life sciences, including CDMOs. Comparable as an emerging vendor bringing modern software and AI to biomanufacturing workflows, though focused on shop-floor execution rather than cross-organizational data federation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Axio BioPharma

Biologics Manufacturing Software & Data Infrastructureaxiobiopharma.com

Axio BioPharma builds a vendor-neutral data network for biopharma, combining a high-throughput monoclonal antibody lab (Forge) in Madison, WI with an in-development federated intelligence platform (Lattice), serving biotech sponsors and CDMOs.

What Axio BioPharma does

Axio BioPharma is a Seed-stage biotechnology company founded in 2024 in Madison, Wisconsin, building a vendor-neutral data network for biopharma. The company operates a platform-plus-modules architecture: Axio Forge is a US-based high-throughput biologics laboratory producing approximately 100 monoclonal antibodies per week with 3-5 week turnaround using CHO and HEK293 expression systems, running on a fee-for-service revenue model. Axio Lattice is a federated intelligence platform in development, comprising four components — Node (local system connections), Rosetta (standardization layer), Blueprints (pre-built workflows), and Signal (pattern surfacing) — designed to connect manufacturing process data across sponsor and CDMO sites without centralizing it, enabling cross-site tech transfer, batch decisions, and investigations via a planned recurring subscription model. The company's BAMI (Biomanufacturing AI Maturity Index) is a six-level assessment framework across five dimensions that functions as thought-leadership content marketing and a top-of-funnel for Lattice adoption.

The company's go-to-market is enterprise field sales targeting two primary customer segments: biotech companies developing biologic therapeutics (seeking faster process understanding and tech transfer) and contract development and manufacturing organizations (seeking to standardize knowledge and scale intelligence across sites). Distribution is single-country/domestic through direct engagement led by Chief Commercial Officer Dave Watrous. The company was founded by Justin Byers (CEO) and Brian Staats (CTO, 20+ years bioinformatics) and has assembled an advisory board including former Catalent VP R&D Greg Bleck, biologics veteran Graham Brearley, Samsung Biologics/Jubilant alumnus Patrick Haffey, and Jim Wilson (ZEA Biosciences CEO, Shepherd Ventures III). Axio was named a Round 1 awardee of the Innovation to Commercialization Pipeline program led by Forward BIOLABS and BioForward Wisconsin in February 2026.

Axio's core competitive thesis is structural neutrality — large CDMOs cannot credibly host a cross-sponsor data network and sponsors will not place proprietary process data on a competitor's platform, so an independent vendor is positioned as the only viable coordinator. The wet-lab Forge engine generates real manufacturing data that seeds the Lattice network, and each deployment compounds reusable schemas and connectors. The company is privately held at Seed stage with approximately $1.4M in disclosed funding; no revenue figures or named customer logos have been disclosed.

Axio BioPharma firmographics

Firmographics
Name
Axio BioPharma
Legal name
Axio BioPharma Inc.
Website
https://axiobiopharma.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Axio BioPharma builds a vendor-neutral data network for biopharma, combining a high-throughput monoclonal antibody lab (Forge) in Madison, WI with an in-development federated intelligence platform (Lattice), serving biotech sponsors and CDMOs.
Ownership category
akta.pro rank

Axio BioPharma industry classification

Industry
Product category
Biologics Manufacturing Software & Data Infrastructure
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAI
AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biologics manufacturing software
  • Monoclonal antibody production
  • Federated data platform
  • Biopharma AI readiness
  • Process development lab

Where Axio BioPharma is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Axio BioPharma business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Axio Forge - Fee-for-Service Lab: Non-GMP antibody lab providing fee-for-service revenue. High-throughput antibody lab generating fee-for-service revenue. Zero incremental capex for current growth. Generates real manufacturing data that seeds the Lattice network.
  2. Axio Lattice - Subscription Platform: Federated data platform with recurring subscription revenue. Vendor-neutral infrastructure connecting manufacturing data across sponsors and CDMOs. Data stays local; meaning is standardized. High-margin recurring revenue model.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goFee-for-service laboratory execution
SubscriptionMonthlyFederated data platform subscription

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Axio BioPharma product offering

Product offering

Core offering

Axio BioPharma provides AI-ready biologics manufacturing through two integrated offerings: Axio Forge, a US-based high-throughput laboratory producing approximately 100 monoclonal antibodies per week with 3–5 week turnaround using CHO and HEK293 expression systems on a fee-for-service basis; and Axio Lattice, a federated intelligence data platform (in development) that connects and standardizes manufacturing process data across sponsor and CDMO sites without replacing existing systems or centralizing raw data. The offerings are supported by the BAMI (Biomanufacturing AI Maturity Index), a six-level framework and self-assessment tool that evaluates AI readiness across five dimensions.

Product overview

Axio BioPharma offers a platform-plus-modules architecture centered on AI-ready biologics manufacturing. The core offerings are Axio Forge (a US-based high-throughput antibody lab providing fee-for-service mAb production) and Axio Lattice (a federated data intelligence platform under development that connects manufacturing data across sponsors and CDMOs without centralizing it). The BAMI (Biomanufacturing AI Maturity Index) assessment framework complements the platform by helping organizations evaluate their AI readiness across five dimensions. Forge generates real execution data that informs Lattice development, while Lattice is designed to enable cross-site process intelligence, investigations, and decision-making.

Differentiator

Problem solved

Functional benefit

Brands

  • Forge: High-throughput monoclonal antibody (mAb) production lab in Madison, WI offering ~100 antibodies/week with 3-5 week turnaround using CHO and HEK293 expression systems.
  • Lattice
  • BAMI

Products and services

  • Axio Forge US-based high-throughput biologics laboratory in Madison, Wisconsin providing fee-for-service monoclonal antibody production. Produces approximately 100 antibodies per week with a 3–5 week turnaround, supporting CHO and HEK293 transient expression systems, Protein A purification, and standard analytics (purity, aggregation, yield). End-to-end workflow from sequence or plasmid to purified antibody with direct bench-scale scientist access and automated DOE.
  • Axio Lattice Federated intelligence data platform (in development) connecting process data across sites, systems, and partners without replacing existing technology stacks or centralizing raw data. Comprises Node (connects to local systems), Rosetta (standardizes structure and terminology), Blueprints (pre-built workflows), and Signal (surfaces patterns and decision support). Supports tech transfer, batch decisions, cross-site comparability, and investigations across sponsors and CDMOs on a recurring subscription model.

Companies that use Axio BioPharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Axio BioPharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Axio BioPharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Forward BIOLABScoreStrategic or Co-development Partner · 3 February 2026Forward BIOLABS leads the Innovation to Commercialization Pipeline (ICP) program in partnership with BioForward Wisconsin. Axio BioPharma was selected as a Round 1 awardee of the ICP program, which supports early-stage biohealth companies across Wisconsin with targeted resources to reduce commercialization risk, accelerate growth, and strengthen investment readiness.
  • BioForward WisconsincoreStrategic or Co-development Partner · 3 February 2026BioForward Wisconsin is the unified voice of Wisconsin's biohealth industry and lead organization for the Wisconsin Biohealth Tech Hub. Partners with Forward BIOLABS on the ICP program to support early-stage biohealth companies including Axio BioPharma.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Axio BioPharma competitors and assessment

Company assessment

Direct peers

  • TetraScience: Provides a federated, vendor-neutral scientific data cloud for life sciences R&D and manufacturing, with AI-ready data lake architecture. Highly comparable to Axio Lattice in approach (data stays local, meaning is standardized) and target customers (biopharma sponsors and CDMOs).
  • Benchling: Cloud-based informatics platform for biotech R&D, including biologics development. Comparable in serving modern, AI-forward biologics teams with structured data capture, though focused upstream of manufacturing where Axio Lattice targets cross-site process intelligence.
  • Sapio Sciences: LIMS/ELN platform with growing AI and lab automation capabilities, serving biopharma and CDMOs. Comparable as an informatics vendor modernizing lab and process data capture for biologics workflows.
  • Genedata: Enterprise biopharma R&D and bioprocess informatics platform used across large biologics sponsors. Comparable as a deep bioprocess data platform targeting similar sponsor customers with structured process data.
  • Dotmatics: Scientific R&D informatics platform (LIMS, ELN, data management) used across biopharma. Comparable as a vendor offering structured data infrastructure that biopharma teams can extend into manufacturing workflows.
  • IDBS: Biopharma data management and process informatics platform with strong bioprocess heritage. Comparable as an established informatics vendor serving biopharma R&D and manufacturing data needs.

Emerging players

  • Aizon: AI platform purpose-built for biopharma manufacturing with GMP data cloud and analytics. Comparable as a focused biomanufacturing AI vendor but more narrowly applied to batch analytics rather than cross-site federated coordination.
  • Apprentice.io: Manufacturing intelligence and execution platform for life sciences, including CDMOs. Comparable as an emerging vendor bringing modern software and AI to biomanufacturing workflows, though focused on shop-floor execution rather than cross-organizational data federation.

Broad incumbents

  • Veeva Systems: Dominant life sciences cloud platform with Vault-based manufacturing, quality, and clinical solutions deeply embedded in pharma sponsors and CDMOs. Comparable as an incumbent data platform, though not vendor-neutral across sponsor/CDMO boundaries — exactly the gap Axio targets.
  • Dassault Systèmes BIOVIA: Scientific informatics suite covering lab, formulation, and bioprocess workflows for large biopharma. Comparable as an incumbent serving biomanufacturing data needs with deep installed base, though typically deployed within single organizations rather than across sponsor/CDMO networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Axio BioPharma social profiles

Digital presence

Axio BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Axio BioPharma leadership team

Management profile

Number of profiles

Profiles7 records

Axio BioPharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Axio BioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axio BioPharma

What does Axio BioPharma do?

Axio BioPharma provides AI-ready biologics manufacturing through two integrated offerings: Axio Forge, a US-based high-throughput laboratory producing approximately 100 monoclonal antibodies per week with 3–5 week turnaround using CHO and HEK293 expression systems on a fee-for-service basis; and Axio Lattice, a federated intelligence data platform (in development) that connects and standardizes manufacturing process data across sponsor and CDMO sites without replacing existing systems or centralizing raw data. The offerings are supported by the BAMI (Biomanufacturing AI Maturity Index), a six-level framework and self-assessment tool that evaluates AI readiness across five dimensions.

Is Axio BioPharma a public or private company?

Axio BioPharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Axio BioPharma founded?

Axio BioPharma was founded in 2024. It employs 1 to 10 people.

Where is Axio BioPharma based?

Axio BioPharma is headquartered in Madison, United States, in the North America region.

How does Axio BioPharma make money?

Two revenue lines are on record. Axio Forge - Fee-for-Service Lab is the primary driver. The others are axio Lattice - Subscription Platform.

Who are Axio BioPharma's main competitors?

Direct peers on record are TetraScience, Benchling, Sapio Sciences, Genedata, Dotmatics and IDBS. Emerging players are Aizon and Apprentice.io. Broad incumbents are Veeva Systems and Dassault Systèmes BIOVIA.

Does Axio BioPharma have an API?

No public API is recorded for Axio BioPharma.

What industry is Axio BioPharma in?

Axio BioPharma's product category is Biologics Manufacturing Software & Data Infrastructure. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAEANAI, AI Integration & Orchestration Platforms (Connectors, Workflow, iPaaS for AI). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAxio Biopharma And Shimadzu Collaborate To Advance AI-Guided Cell Culture Media OptimizationAxio BioPharma and Shimadzu announced a collaboration to combine Shimadzu's CellTune Ver.2 software and Media Blending Kit with Axio's Madison laboratory for cell culture media optimization. The partnership aims to integrate AI-guided experimental design with high-throughput lab execution to improve antibody expression workflows. Results will be shared separately after completion.EIN PresswireAxio BioPharma and Shimadzu Collaborate to Advance AI-Guided Cell Culture Media OptimizationAxio BioPharma and Shimadzu announced a collaboration to combine Shimadzu's CellTune Ver.2 software and Media Blending Kit with Axio's Madison laboratory for AI-guided cell culture media optimization. The partnership aims to integrate computational design with wet-lab execution to improve antibody expression workflows. Results will be shared separately after completion.EIN PresswireAxio BioPharma and Shimadzu Collaborate to Advance AI-Guided Cell Culture Media OptimizationAxio BioPharma and Shimadzu announced a collaboration to optimize cell culture media for biologics, combining Shimadzu's CellTune Ver.2 software and Media Blending Kit with Axio's Madison laboratory. The partnership aims to integrate AI-guided experimental design with high-throughput wet-lab execution to improve antibody expression workflows.EIN PresswireAxio BioPharma and Elucidata Partner to Connect R&D Data with Biomanufacturing WorkflowsAxio BioPharma and Elucidata announced a partnership to improve data continuity as biopharma programs move from research into process development and manufacturing. The collaboration combines Elucidata's Polly platform for data harmonization with Axio Lattice's federated network, aiming to preserve scientific context across organizational boundaries.FinSMEsAxio BioPharma Raises $2.4M in Pre Seed FundingAxio BioPharma, a Madison, WI-based pharma data platform, raised $2.4M in pre-seed financing from Elmstead Partners, Chisos Capital, the Chemical Angel Network, and individual angels. The company will use the funds to support initial deployments of Axio Lattice and continued development of Rosetta, its ontology mapping layer.EIN PresswireAxio BioPharma Raises $2.4 Million to Connect Manufacturing Data Across CompaniesAxio BioPharma closed a $2.4 million pre-seed round to fund initial deployments of its Axio Lattice platform, which connects manufacturing data across pharma and manufacturing partners. The funding will also support development of Rosetta, Lattice's ontology mapping layer. The company plans to work with design partners on workflows where cross-company data gaps create friction.AxiobiopharmaAxio BioPharma Raises $2.4 Million to Connect Manufacturing Data Across CompaniesAxio BioPharma closed a $2.4 million pre-seed round to fund initial deployments of its Axio Lattice platform, which connects manufacturing data across pharma and manufacturing partners. The funding also supports development of Rosetta, its ontology mapping layer, and the company plans to work with design partners on cross-company data gaps.AxiobiopharmaAxio BioPharma Selected for Plug and Play Lifetech Accelerator’s Third CohortAxio BioPharma was selected for Batch 3 of Plug and Play's Lifetech Accelerator, joining 12 startups. The program provides mentorship and industry engagement around Axio's Lattice and Forge business lines. Axio will participate in fall programming, including Lifetech Focus Days and the Lifetech Expo in December.EIN PresswireAxio BioPharma Selected for Plug and Play Lifetech Accelerator’s Third CohortAxio BioPharma was selected for Batch 3 of the Plug and Play Lifetech Accelerator, one of 12 startups. The program will support industry engagement around Axio's Lattice and Forge, with fall programming including Lifetech Focus Days and Expo. The accelerator is conducted with Indiana University, IU Health, and BioCrossroads.EIN PresswireAxio BioPharma Selects Ansa Biotechnologies as Preferred Gene Synthesis ProviderAxio BioPharma named Ansa Biotechnologies as its preferred gene synthesis provider, routing gene synthesis for its high-throughput antibody lab, Axio Forge. Ansa's platform offers a 3-5 week turnaround and an on-time guarantee, aiming to reduce schedule risk in antibody production workflows.